post-translational modification, glycans, glycosylation, cancer, cholangiocarcinoma, glioblastoma, meningioma, melanoma, melanogenesis, biomarkers



Jun 2005 – Dec 2010 Ph.D. Medical Biochemistry, Khon Kaen University, Thailand
Jun 2000 – Mar 2004 B.Sc. Medical Technology, Khon Kaen University, Thailand

Post-Graduate Training

2014-2016 JSPS International Research Fellow of Department of Tumor Genetics and Biology, Kumamoto University, Kumamoto, Japan


The 2020 Professor Jisnusan Svasti Young Protein Scientist of Thailand Award, Protein Society of Thailand

Outstanding Biomedical Research Award (Young PI, age < 40 years) 2017, Faculty of Medicine, Khon Kaen University, Thailand

Cancer Sciences Young Scientist Award 2014, Japanese Cancer Association (JCA), Japan

My research of interest

My research focuses on the involvement of post-translational modification (PTM), called “glycosylation”, in human diseases.  I am now working on the role of glycans and glycosylation in the progression of cancers, such as cholangiocarcinoma, glioblastoma, meningioma, and melanoma. In addition, my interest is expanded into the significance of glycans and glycosylation in melanogenesis. The glycans and glycosylation are potentially applied as a biomarker for the detection of diseases or as a target for the treatment of human diseases and cosmetic concerns. My recent research activities are as follows.

1. Glycosylation and its roles in the progression of cancers and cancer stem cells (such as meningioma, glioblastoma, melanoma, etc.)

In cancer and cancer stem cell cells, alteration of glycosylation led to the aberrant expression of glycans and was found to play essential roles in tumor development and progression.  Based on our previous studies, glycosylation was found to promote tumor growth, metastasis, and chemoresistance. Suppression of the glycans and glycosylation significantly reduce the aggressiveness of cancer cells.  As they play significant roles in tumor development and progression, their role as a target for treatment is also renowned. My research interest is identifying the tumor-associated glycans and exploring their roles in tumor progression and therapeutic resistance.   Our studies aim to apply them as a target for the treatment of cancers in the future.

2. Glycobiomarkers for diagnosis and prognostic prediction of cancers

Not only promote cancer progression, but the tumor-associated glycans aberrantly expressed in tumors were also the potential biomarkers for diagnosis and prognostic prediction of the diseases. My interest is to use the tumor-associated glycans for diagnosis, monitoring, and prognostic prediction of benign and malignant tumors, such as meningioma and glioblastoma.  We used lectin-assisted approaches to develop the assays and apply them to detect glycans in clinical samples, such as serum, plasma, CSF, end, etc

3. Golgi stress and glycosylation

The Golgi apparatus is a vital organelle that regulates many cellular processes.  The stress of the Golgi apparatus, called “Golgi stress”, affects many cellular processes, such as protein targeting, lysosome formation, as well as glycosylation.  We aimed to explore the association of Golgi stress to the progression of meningioma and glioblastoma through the glycosylation process.  The Golgi stress and glycosylation might be a good candidate for the treatment of meningioma and glioblastoma in the future.

4. Glycosylation and melanogenesis

The overproduction of melanin in melanocytes causes skin hyperpigmentation.  Several factors, such as UV exposure and the aging process, contribute significantly to abnormal melanogenesis.  It is little known about the role of glycosylation on melanogenesis. Therefore, we aim to explore the contribution of glycans and glycosylation to melanogenesis.  The glycosylation and glycans might be a potential target for treating hyperpigmentation in the future.

Academic Society/Editorial Board Membership

  1. Executive Committee Members (2021 – 2023), Protein Society of Thailand
  2. Editorial Board (May 2021 – Current), Experimental and Therapeutic Medicine (ISSN: 1792-1015)
  3. Editorial Board (Jan 2022 – Dec 2025), World Journal of Biological Chemistry (ISSN: 1949-8454)
  4. Editorial Board (Mar 2022- Feb 2025), Journal of Modern Medicinal Chemistry (ISSN: 2308-8044)


Book chapters:

  1. Silsirivanit, A.*, Phoomak, C., Wongkham, S. (2021). Glycosylation in cholangiocarcinoma development and metastasis: diagnostic and therapeutic considerations. In: Tabibian J.H. (eds) Diagnosis and Management of Cholangiocarcinoma. Springer, Cham. (*correspondence)
  2. Silsirivanit, A*. (2019). Glycosylation markers in cancer. Adv Clin Chem, 89, 189-213.  (IF2019 = 5.394, *correspondence)


  • Silsirivanit, A*. (2021). Glycans: potential therapeutic targets for cholangiocarcinoma and their therapeutic and diagnostic implications. Expert Opin Ther Targets, 25(1), 1-4.  (IF2020 = 6.902, *correspondence)

Review articles:

  1. Silsirivanit, A., Sawanyawisuth, K., Riggins, G. J., & Wongkham, C. (2014). Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches. J Hepatobiliary Pancreat Sci, 21(6), 388-396. (IF2020 = 7.027)
  2. Wongkham, S., & Silsirivanit, A. (2012). State of serum markers for detection of cholangiocarcinoma. Asian Pac J Cancer Prev, 13 Suppl, 17-27. (IF2014 = 2.514)

Selected research articles:

  1. Putthisen, S., Silsirivanit, A., Panawan, O., Niibori-Nambu, A., Nishiyama-Ikeda, Y., Main, P., Luang, S., Ohta, K., Muisuk, K., Wongkham, S., & Araki, N. (2021). Targeting alpha2,3- sialylated glycan in glioma stem-like cells by Maackia amurensis lectin-II: A promising strategy for glioma treatment. Exp Cell Res, 112949.  (IF2020 = 3.905, *correspondence)
  2. Teeravirote, K., Luang, S., Waraasawapati, S., Boonsiri, P., Wongkham, C., Wongkham, S., & Silsirivanit, A*. (2021). A novel serum glycobiomarker for diagnosis and prognosis of cholangiocarcinoma detected by Butea monosperma agglutinin. Molecules, 26(9).  (IF2020 = 4.411, *correspondence)
  3. Silsirivanit, A.*, Matsuda, A., Kuno, A., Tsuruno, C., Uenoyama, Y., Seubwai, W., Angata, K., Teeravirote, K., Wongkham, C., Araki, N., Takahama, Y., Wongkham, S., & Narimatsu, H. (2020). Multi-serum glycobiomarkers improves the diagnosis and prognostic prediction of cholangiocarcinoma. Clin Chim Acta, 510, 142-149.  (IF2020 = 3.786, *correspondence)
  4. Luang, S., Teeravirote, K., Saentaweesuk, W., Ma-In, P., & Silsirivanit, A.* (2020). Carbohydrate antigen 50: values for diagnosis and prognostic prediction of intrahepatic cholangiocarcinoma. Medicina (Kaunas), 56(11). (IF2020 = 2.430, *correspondence)
  5. Detarya, M., Sawanyawisuth, K., Aphivatanasiri, C., Chuangchaiya, S., Saranaruk, P., Sukprasert, L., Silsirivanit, A., Araki, N., Wongkham, S., & Wongkham, C. (2020). The O-GalNAcylating enzyme GALNT5 mediates carcinogenesis and progression of cholangiocarcinoma via activation of AKT/ERK signaling. Glycobiology, 30(5), 312-324.  (IF2020 = 4.313)
  6. Silsirivanit, A., Phoomak, C., Teeravirote, K., Wattanavises, S., Seubwai, W., Saengboonmee, C., Zhan, Z., Inokuchi, J. I., Suzuki, A., & Wongkham, S. (2019). Overexpression of HexCer and LacCer containing 2-hydroxylated fatty acids in cholangiocarcinoma and the association of the increase of LacCer (d18:1-h23:0) with shorter survival of the patients. Glycoconj J, 36(2), 103-111.  (IF2020 = 2.916)
  7. Wattanavises, S., Silsirivanit, A.*, Sawanyawisuth, K., Cha’on, U., Waraasawapati, S., Saentaweesuk, W., Luang, S., Chalermwat, C., Wongkham, C., & Wongkham, S. (2019). Increase of MAL-II binding alpha2,3-sialylated glycan is associated with 5-FU resistance and short survival of cholangiocarcinoma patients. Medicina (Kaunas), 55(12). (IF2020 = 2.430, *correspondence)
  8. Phoomak, C., Park, D., Silsirivanit, A., Sawanyawisuth, K., Vaeteewoottacharn, K., Detarya, M., Wongkham, C., Lebrilla, C. B., & Wongkham, S. (2019). O-GlcNAc-induced nuclear translocation of hnRNP-K is associated with progression and metastasis of cholangiocarcinoma. Mol Oncol, 13(2), 338-357.  (IF2020 = 6.603)
  9. Indramanee, S., Sawanyawisuth, K., Silsirivanit, A., Dana, P., Phoomak, C., Kariya, R., Klinhom-On, N., Sorin, S., Wongkham, C., Okada, S., & Wongkham, S. (2019). Terminal fucose mediates progression of human cholangiocarcinoma through EGF/EGFR activation and the Akt/Erk signaling pathway. Sci Rep, 9(1), 17266.  (IF2020 = 4.379)
  10. Sittithumcharee, G., Suppramote, O., Vaeteewoottacharn, K., Sirisuksakun, C., Jamnongsong, S., Laphanuwat, P., Suntiparpluacha, M., Matha, A., Chusorn, P., Buraphat, P., Kakanaporn, C., Charngkaew, K., Silsirivanit, A., Korphaisarn, K., Limsrichamrern, S., Tripatara, P., Pairojkul, C., Wongkham, S., Sampattavanich, S., Okada, S., & Jirawatnotai, S. (2019). Dependency of cholangiocarcinoma on cyclin D-dependent kinase activity. Hepatology, 70(5), 1614-1630.  (IF2020 = 17.425)
  11. Vaeteewoottacharn, K., Pairojkul, C., Kariya, R., Muisuk, K., Imtawil, K., Chamgramol, Y., Bhudhisawasdi, V., Khuntikeo, N., Pugkhem, A., Saeseow, O. T., Silsirivanit, A., Wongkham, C., Wongkham, S., & Okada, S. (2019). Establishment of highly transplantable cholangiocarcinoma cell lines from a patient-derived xenograft mouse model. Cells, 8(5).  (IF2020 = 6.600)
  12. Saentaweesuk, W., Silsirivanit, A.*, Vaeteewoottacharn, K., Sawanyawisuth, K., Pairojkul, C., Cha’on, U., Indramanee, S., Pinlaor, S., Boonmars, T., Araki, N., & Wongkham, C. (2018). Clinical significance of GalNAcylated glycans in cholangiocarcinoma: Values for diagnosis and prognosis. Clin Chim Acta, 477, 66-71.  (IF2020 = 3.786, *correspondence)
  13. Phoomak, C., Silsirivanit, A., Park, D., Sawanyawisuth, K., Vaeteewoottacharn, K., Wongkham, C., Lam, E. W., Pairojkul, C., Lebrilla, C. B., & Wongkham, S. (2018). O-GlcNAcylation mediates metastasis of cholangiocarcinoma through FOXO3 and MAN1A1. Oncogene, 37(42), 5648-5665.  (IF2020 = 9.867)
  14. Saentaweesuk, W., Araki, N., Vaeteewoottacharn, K., Silsirivanit, A., Seubwai, W., Talabnin, C., Muisuk, K., Sripa, B., Wongkham, S., Okada, S., & Wongkham, C. (2018). Activation of vimentin is critical to promote a metastatic potential of cholangiocarcinoma cells. Oncol Res, 26(4), 605-616.  (IF2020 = 5.574)
  15. Thi Do, T., Phoomak, C., Champattanachai, V., Silsirivanit, A., & Chaiyarit, P. (2018). New evidence of connections between increased O-GlcNAcylation and inflammasome in the oral mucosa of patients with oral lichen planus. Clin Exp Immunol, 192(1), 129-137.  (IF2020 = 4.330)
  16. Phoomak, C., Vaeteewoottacharn, K., Silsirivanit, A., Saengboonmee, C., Seubwai, W., Sawanyawisuth, K., Wongkham, C., & Wongkham, S. (2017). High glucose levels boost the aggressiveness of highly metastatic cholangiocarcinoma cells via O-GlcNAcylation. Sci Rep, 7, 43842.  (IF2020 = 4.379)
  17. Phoomak, C., Vaeteewoottacharn, K., Sawanyawisuth, K., Seubwai, W., Wongkham, C., Silsirivanit, A.*, & Wongkham, S. (2016). Mechanistic insights of O-GlcNAcylation that promote progression of cholangiocarcinoma cells via nuclear translocation of NF-kappaB. Sci Rep, 6, 27853.  (IF2020 = 4.379, *correspondence)
  18. Pattanapairoj, S., Silsirivanit, A.#, Muisuk, K., Seubwai, W., Cha’on, U., Vaeteewoottacharn, K., Sawanyawisuth, K., Chetchotsak, D., & Wongkham, S. (2015). Improve discrimination power of serum markers for diagnosis of cholangiocarcinoma using data mining-based approach. Clin Biochem, 48(10-11), 668-673.  (IF2020 = 3.281, #co-first author)
  19. Silsirivanit, A., Araki, N., Wongkham, C., Vaeteewoottacharn, K., Pairojkul, C., Kuwahara, K., Narimatsu, Y., Sawaki, H., Narimatsu, H., Okada, S., Sakaguchi, N., & Wongkham, S. (2013). CA-S27: a novel Lewis a associated carbohydrate epitope is diagnostic and prognostic for cholangiocarcinoma. Cancer Sci, 104(10), 1278-1284.  (IF2020 = 6.716)
  20. Sawanyawisuth, K., Silsirivanit, A., Kunlabut, K., Tantapotinan, N., Vaeteewoottacharn, K., & Wongkham, S. (2012). A novel carbohydrate antigen expression during development of Opisthorchis viverrini– associated cholangiocarcinoma in golden hamster: a potential marker for early diagnosis. Parasitol Int, 61(1), 151-154.  (IF2020 = 2.230)
  21. Phoomak, C., Silsirivanit, A.*, Wongkham, C., Sripa, B., Puapairoj, A., & Wongkham, S. (2012). Overexpression of O-GlcNAc-transferase associates with aggressiveness of mass-forming cholangiocarcinoma. Asian Pac J Cancer Prev, 13 Suppl, 101-105.  (IF2014 = 2.514, *correspondence)
  22. Indramanee, S., Silsirivanit, A., Pairojkul, C., Wongkham, C., & Wongkham, S. (2012). Aberrant glycosylation in cholangiocarcinoma demonstrated by lectin-histochemistry. Asian Pac J Cancer Prev, 13 Suppl, 119-124.  (IF2014 = 2.514)
  23. Silsirivanit, A., Araki, N., Wongkham, C., Pairojkul, C., Narimatsu, Y., Kuwahara, K., Narimatsu, H., Wongkham, S., & Sakaguchi, N. (2011). A novel serum carbohydrate marker on mucin 5AC: values for diagnostic and prognostic indicators for cholangiocarcinoma. Cancer, 117(15), 3393-3403.  (IF2020 = 6.860)